Cargando…
Tocilizumab for faster and safer remission of Takayasu’s arteritis
PURPOSE: Takayasu’s arteritis (TAK) is a large-vessel vasculitis. Glucocorticoids (GCs) combined with cyclophosphamide (CTX) is a common treatment option, but their efficacy is limited. The aim of this retrospective study was to study the efficacy and safety of tocilizumab (TCZ) in the treatment of...
Autores principales: | Liao, Hua, Du, Juan, Li, Taotao, Pan, Lili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618741/ https://www.ncbi.nlm.nih.gov/pubmed/36324988 http://dx.doi.org/10.1177/20406223221131715 |
Ejemplares similares
-
Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu’s arteritis: a case-control study
por: Pan, Lili, et al.
Publicado: (2017) -
FDG-PET of Takayasu’s Arteritis
por: Shikino, Kiyoshi, et al.
Publicado: (2014) -
Intracranial Involvement in Takayasu’s Arteritis
por: Johnson, Andrea, et al.
Publicado: (2021) -
Tofacitinib in patients with refractory Takayasu’s arteritis
por: Li, Jing, et al.
Publicado: (2020) -
Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review
por: Prieto-Peña, Diana, et al.
Publicado: (2021)